| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 145 | 2026 | 765 | 16.010 |
Why?
|
| Amyloid beta-Peptides | 107 | 2026 | 321 | 9.280 |
Why?
|
| tau Proteins | 97 | 2026 | 210 | 8.390 |
Why?
|
| Biomarkers | 139 | 2026 | 1476 | 8.130 |
Why?
|
| Insulin Receptor Substrate Proteins | 19 | 2026 | 61 | 7.040 |
Why?
|
| Cognitive Dysfunction | 51 | 2026 | 350 | 5.710 |
Why?
|
| Peptide Fragments | 55 | 2026 | 417 | 4.710 |
Why?
|
| Immunosuppressive Agents | 48 | 2010 | 380 | 4.150 |
Why?
|
| Mycophenolic Acid | 35 | 2010 | 68 | 4.040 |
Why?
|
| Breast Neoplasms | 26 | 2026 | 1217 | 3.100 |
Why?
|
| Positron-Emission Tomography | 39 | 2026 | 232 | 2.590 |
Why?
|
| Humans | 413 | 2026 | 64956 | 2.390 |
Why?
|
| Parkinson Disease | 16 | 2024 | 135 | 2.330 |
Why?
|
| Drug Monitoring | 29 | 2025 | 202 | 2.100 |
Why?
|
| Kidney Transplantation | 28 | 2010 | 324 | 1.940 |
Why?
|
| Immunoassay | 17 | 2023 | 71 | 1.910 |
Why?
|
| Neuroimaging | 20 | 2026 | 163 | 1.900 |
Why?
|
| Signal Transduction | 20 | 2026 | 3143 | 1.790 |
Why?
|
| Frontotemporal Lobar Degeneration | 11 | 2023 | 20 | 1.740 |
Why?
|
| Female | 209 | 2026 | 33929 | 1.580 |
Why?
|
| Aged | 131 | 2026 | 14926 | 1.580 |
Why?
|
| Tacrolimus | 21 | 2010 | 63 | 1.550 |
Why?
|
| Neuropsychological Tests | 26 | 2024 | 410 | 1.540 |
Why?
|
| Disease Progression | 33 | 2026 | 1214 | 1.490 |
Why?
|
| Phosphoproteins | 7 | 2019 | 224 | 1.460 |
Why?
|
| Tooth Erosion | 21 | 2003 | 21 | 1.390 |
Why?
|
| Male | 198 | 2026 | 30955 | 1.380 |
Why?
|
| Neoplasm Proteins | 5 | 2021 | 285 | 1.340 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2021 | 215 | 1.330 |
Why?
|
| Neoplasm Invasiveness | 14 | 2018 | 286 | 1.290 |
Why?
|
| Frontotemporal Dementia | 9 | 2023 | 157 | 1.230 |
Why?
|
| Phosphorylation | 27 | 2026 | 961 | 1.200 |
Why?
|
| Aged, 80 and over | 64 | 2026 | 5601 | 1.170 |
Why?
|
| Graft Rejection | 19 | 2010 | 302 | 1.150 |
Why?
|
| Cyclosporine | 20 | 2009 | 77 | 1.150 |
Why?
|
| Middle Aged | 108 | 2026 | 18210 | 1.140 |
Why?
|
| Lewy Body Disease | 7 | 2025 | 15 | 1.140 |
Why?
|
| Brain | 26 | 2026 | 1601 | 1.080 |
Why?
|
| alpha-Synuclein | 9 | 2025 | 38 | 1.030 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 2018 | 55 | 0.990 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2026 | 343 | 0.980 |
Why?
|
| Integrins | 10 | 2002 | 109 | 0.980 |
Why?
|
| Neoplasms | 7 | 2022 | 1365 | 0.980 |
Why?
|
| Mass Spectrometry | 10 | 2024 | 295 | 0.970 |
Why?
|
| Cognition Disorders | 13 | 2014 | 223 | 0.970 |
Why?
|
| Cognition | 17 | 2026 | 503 | 0.960 |
Why?
|
| Neurodegenerative Diseases | 7 | 2024 | 151 | 0.960 |
Why?
|
| Amifostine | 13 | 2002 | 14 | 0.940 |
Why?
|
| Albumins | 1 | 2026 | 43 | 0.930 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2026 | 730 | 0.930 |
Why?
|
| Cell Line, Tumor | 17 | 2026 | 1564 | 0.920 |
Why?
|
| Brain Injuries, Traumatic | 3 | 2026 | 94 | 0.920 |
Why?
|
| Mitosis | 2 | 2026 | 222 | 0.890 |
Why?
|
| Busulfan | 7 | 2025 | 18 | 0.890 |
Why?
|
| Sirolimus | 9 | 2010 | 93 | 0.870 |
Why?
|
| Indoleacetic Acids | 1 | 2024 | 31 | 0.860 |
Why?
|
| Clinical Chemistry Tests | 3 | 2020 | 6 | 0.850 |
Why?
|
| Cell Cycle Proteins | 2 | 2026 | 402 | 0.820 |
Why?
|
| Stress, Physiological | 1 | 2026 | 209 | 0.820 |
Why?
|
| Apolipoproteins E | 15 | 2026 | 115 | 0.800 |
Why?
|
| Tandem Mass Spectrometry | 8 | 2021 | 137 | 0.800 |
Why?
|
| Integrin alpha6beta4 | 7 | 2010 | 44 | 0.780 |
Why?
|
| Glial Fibrillary Acidic Protein | 4 | 2025 | 41 | 0.780 |
Why?
|
| Somatomedins | 1 | 2022 | 4 | 0.770 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2021 | 83 | 0.760 |
Why?
|
| Phosphatidylinositol 3-Kinases | 6 | 2022 | 178 | 0.740 |
Why?
|
| Kidney Failure, Chronic | 8 | 2016 | 196 | 0.740 |
Why?
|
| Apolipoprotein E4 | 12 | 2023 | 46 | 0.740 |
Why?
|
| Beclin-1 | 2 | 2019 | 22 | 0.730 |
Why?
|
| Amyloidogenic Proteins | 3 | 2022 | 13 | 0.720 |
Why?
|
| Chromatography, High Pressure Liquid | 30 | 2021 | 223 | 0.700 |
Why?
|
| Cerebrospinal Fluid | 1 | 2021 | 29 | 0.690 |
Why?
|
| Liver Transplantation | 13 | 2004 | 219 | 0.690 |
Why?
|
| RNA, Small Interfering | 3 | 2026 | 980 | 0.690 |
Why?
|
| Receptors, Somatomedin | 2 | 2018 | 10 | 0.690 |
Why?
|
| Longitudinal Studies | 24 | 2026 | 1280 | 0.680 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2021 | 23 | 0.670 |
Why?
|
| Plaque, Amyloid | 7 | 2023 | 41 | 0.650 |
Why?
|
| Cohort Studies | 28 | 2026 | 2614 | 0.640 |
Why?
|
| Postoperative Complications | 4 | 2025 | 1314 | 0.630 |
Why?
|
| Cross-Sectional Studies | 23 | 2026 | 2702 | 0.630 |
Why?
|
| Phosphatidylinositol 3-Kinase | 2 | 2022 | 14 | 0.620 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2020 | 25 | 0.620 |
Why?
|
| Neurofilament Proteins | 5 | 2025 | 25 | 0.610 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2026 | 583 | 0.600 |
Why?
|
| Radiation-Protective Agents | 5 | 2002 | 9 | 0.600 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2019 | 61 | 0.590 |
Why?
|
| Electrochemical Techniques | 1 | 2019 | 21 | 0.590 |
Why?
|
| Area Under Curve | 20 | 2025 | 149 | 0.590 |
Why?
|
| Atrophy | 9 | 2025 | 87 | 0.590 |
Why?
|
| Animals | 49 | 2026 | 21292 | 0.580 |
Why?
|
| IMP Dehydrogenase | 7 | 2008 | 9 | 0.580 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 166 | 0.580 |
Why?
|
| Endosomes | 2 | 2019 | 180 | 0.570 |
Why?
|
| Receptor, IGF Type 1 | 4 | 2021 | 30 | 0.570 |
Why?
|
| Chromatography, Liquid | 9 | 2021 | 117 | 0.560 |
Why?
|
| Adult | 73 | 2022 | 17313 | 0.550 |
Why?
|
| Prospective Studies | 25 | 2025 | 3305 | 0.550 |
Why?
|
| Carcinoma, Lobular | 1 | 2018 | 26 | 0.540 |
Why?
|
| Protein Binding | 17 | 2026 | 1639 | 0.540 |
Why?
|
| Tyrosine | 6 | 2017 | 93 | 0.530 |
Why?
|
| Models, Biological | 6 | 2025 | 1192 | 0.530 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 703 | 0.520 |
Why?
|
| Ethylene Glycols | 6 | 2022 | 11 | 0.520 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 184 | 0.510 |
Why?
|
| Mutation | 10 | 2020 | 2657 | 0.510 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 260 | 0.510 |
Why?
|
| Magnetic Resonance Imaging | 23 | 2025 | 2240 | 0.510 |
Why?
|
| Dementia | 5 | 2024 | 280 | 0.500 |
Why?
|
| Reproducibility of Results | 28 | 2021 | 1692 | 0.500 |
Why?
|
| Aniline Compounds | 8 | 2025 | 40 | 0.490 |
Why?
|
| Cell Proliferation | 6 | 2026 | 1036 | 0.490 |
Why?
|
| Kidney | 11 | 2009 | 450 | 0.470 |
Why?
|
| Genome-Wide Association Study | 8 | 2026 | 361 | 0.470 |
Why?
|
| Microtubules | 1 | 2017 | 210 | 0.470 |
Why?
|
| Cyclosporins | 9 | 1990 | 17 | 0.470 |
Why?
|
| MicroRNAs | 3 | 2024 | 710 | 0.460 |
Why?
|
| Hippocampus | 10 | 2023 | 274 | 0.450 |
Why?
|
| Substance Abuse Detection | 3 | 2021 | 39 | 0.450 |
Why?
|
| Receptors, Growth Factor | 1 | 2015 | 19 | 0.450 |
Why?
|
| Digoxin | 5 | 2000 | 23 | 0.440 |
Why?
|
| Autopsy | 4 | 2022 | 56 | 0.430 |
Why?
|
| Anesthetics | 3 | 2025 | 13 | 0.430 |
Why?
|
| Enzyme Inhibitors | 5 | 2008 | 367 | 0.430 |
Why?
|
| Glucose | 3 | 2018 | 476 | 0.430 |
Why?
|
| Mice | 21 | 2026 | 11088 | 0.420 |
Why?
|
| Reference Standards | 12 | 2025 | 76 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 706 | 0.420 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 152 | 0.420 |
Why?
|
| Tauopathies | 3 | 2023 | 17 | 0.420 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2014 | 46 | 0.420 |
Why?
|
| Glycolysis | 1 | 2014 | 59 | 0.410 |
Why?
|
| Child | 27 | 2025 | 4606 | 0.400 |
Why?
|
| Clinical Trials as Topic | 5 | 2024 | 460 | 0.390 |
Why?
|
| Adolescent | 38 | 2025 | 6293 | 0.390 |
Why?
|
| Gray Matter | 3 | 2024 | 38 | 0.390 |
Why?
|
| Cell Survival | 6 | 2026 | 587 | 0.380 |
Why?
|
| Antigens, Surface | 4 | 2002 | 199 | 0.380 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2026 | 509 | 0.380 |
Why?
|
| Early Diagnosis | 4 | 2020 | 95 | 0.370 |
Why?
|
| Membrane Proteins | 2 | 2016 | 918 | 0.370 |
Why?
|
| Cell Membrane | 4 | 2016 | 505 | 0.360 |
Why?
|
| Risk Factors | 19 | 2025 | 5410 | 0.360 |
Why?
|
| Delirium | 2 | 2025 | 55 | 0.350 |
Why?
|
| Heart Transplantation | 5 | 2005 | 180 | 0.350 |
Why?
|
| Retrospective Studies | 18 | 2025 | 6844 | 0.350 |
Why?
|
| Aging | 7 | 2024 | 764 | 0.350 |
Why?
|
| Beverages | 11 | 2002 | 68 | 0.350 |
Why?
|
| Cholesterol | 3 | 2022 | 261 | 0.340 |
Why?
|
| Prodromal Symptoms | 3 | 2019 | 13 | 0.340 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 168 | 0.330 |
Why?
|
| White Matter | 2 | 2024 | 125 | 0.330 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2010 | 6 | 0.330 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2010 | 17 | 0.330 |
Why?
|
| Body Weight | 2 | 2025 | 374 | 0.330 |
Why?
|
| Neoplasm Metastasis | 4 | 2008 | 221 | 0.330 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 44 | 0.330 |
Why?
|
| Laminin | 5 | 2005 | 81 | 0.330 |
Why?
|
| Serum Albumin | 5 | 2019 | 47 | 0.330 |
Why?
|
| Cell Movement | 8 | 2015 | 480 | 0.320 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2007 | 345 | 0.320 |
Why?
|
| Isoflurane | 2 | 2023 | 16 | 0.320 |
Why?
|
| Transplantation Conditioning | 5 | 2025 | 101 | 0.320 |
Why?
|
| Electroencephalography | 2 | 2025 | 149 | 0.320 |
Why?
|
| Propofol | 2 | 2023 | 21 | 0.320 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2025 | 33 | 0.310 |
Why?
|
| Child, Preschool | 21 | 2025 | 2052 | 0.310 |
Why?
|
| Genotype | 12 | 2023 | 673 | 0.300 |
Why?
|
| Membrane Glycoproteins | 4 | 2020 | 662 | 0.300 |
Why?
|
| gamma-Glutamyltransferase | 9 | 1983 | 16 | 0.300 |
Why?
|
| Blood Proteins | 5 | 2009 | 84 | 0.300 |
Why?
|
| Triglycerides | 2 | 2020 | 248 | 0.300 |
Why?
|
| Depressive Disorder | 1 | 2012 | 284 | 0.300 |
Why?
|
| Follow-Up Studies | 14 | 2022 | 2482 | 0.290 |
Why?
|
| Antigens, CD | 2 | 2021 | 342 | 0.290 |
Why?
|
| Glucuronates | 5 | 1999 | 5 | 0.290 |
Why?
|
| Sex Characteristics | 4 | 2019 | 211 | 0.290 |
Why?
|
| Prodrugs | 3 | 1999 | 36 | 0.290 |
Why?
|
| Neoplastic Stem Cells | 3 | 2022 | 195 | 0.280 |
Why?
|
| Prognosis | 7 | 2024 | 1775 | 0.280 |
Why?
|
| Bile Acids and Salts | 2 | 2018 | 25 | 0.280 |
Why?
|
| Organ Transplantation | 5 | 2006 | 46 | 0.280 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2008 | 52 | 0.280 |
Why?
|
| Amyloidosis | 2 | 2022 | 70 | 0.280 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2024 | 698 | 0.280 |
Why?
|
| Reference Values | 12 | 2019 | 327 | 0.270 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2019 | 449 | 0.270 |
Why?
|
| Tumor Cells, Cultured | 8 | 2014 | 426 | 0.260 |
Why?
|
| Patient Safety | 2 | 2021 | 258 | 0.260 |
Why?
|
| Drug Therapy, Combination | 10 | 2012 | 461 | 0.260 |
Why?
|
| Geriatric Assessment | 3 | 2021 | 160 | 0.260 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2022 | 515 | 0.260 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 521 | 0.250 |
Why?
|
| Receptor, Insulin | 2 | 2021 | 52 | 0.250 |
Why?
|
| Sensitivity and Specificity | 11 | 2024 | 1161 | 0.250 |
Why?
|
| Spinal Puncture | 3 | 2022 | 15 | 0.250 |
Why?
|
| Temporal Lobe | 2 | 2024 | 46 | 0.250 |
Why?
|
| Carbolines | 3 | 2022 | 8 | 0.250 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2006 | 29 | 0.250 |
Why?
|
| Infant | 15 | 2025 | 1683 | 0.240 |
Why?
|
| Receptors, Immunologic | 4 | 2020 | 179 | 0.240 |
Why?
|
| RNA Interference | 4 | 2026 | 643 | 0.240 |
Why?
|
| Databases as Topic | 2 | 2003 | 49 | 0.240 |
Why?
|
| Central Nervous System Diseases | 2 | 2025 | 57 | 0.240 |
Why?
|
| Gingival Overgrowth | 2 | 2002 | 2 | 0.240 |
Why?
|
| CDC2 Protein Kinase | 1 | 2026 | 38 | 0.240 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2009 | 128 | 0.240 |
Why?
|
| Saliva | 3 | 2003 | 100 | 0.240 |
Why?
|
| Mercaptoethylamines | 4 | 2000 | 4 | 0.230 |
Why?
|
| Transplantation, Homologous | 4 | 2012 | 250 | 0.230 |
Why?
|
| Centrosome | 1 | 2026 | 72 | 0.230 |
Why?
|
| Gastroesophageal Reflux | 4 | 2000 | 93 | 0.230 |
Why?
|
| Hepatitis C | 2 | 2006 | 145 | 0.230 |
Why?
|
| Organothiophosphorus Compounds | 5 | 1988 | 7 | 0.230 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2026 | 84 | 0.230 |
Why?
|
| Emergence Delirium | 1 | 2025 | 2 | 0.230 |
Why?
|
| HeLa Cells | 2 | 2026 | 541 | 0.230 |
Why?
|
| Alpha Rhythm | 1 | 2025 | 3 | 0.230 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2025 | 6 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2025 | 856 | 0.220 |
Why?
|
| Case-Control Studies | 10 | 2025 | 1138 | 0.220 |
Why?
|
| Transplantation | 4 | 2000 | 10 | 0.220 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2024 | 2 | 0.220 |
Why?
|
| C9orf72 Protein | 6 | 2020 | 114 | 0.220 |
Why?
|
| Biological Specimen Banks | 1 | 2024 | 23 | 0.220 |
Why?
|
| Protein Transport | 4 | 2017 | 404 | 0.210 |
Why?
|
| Insulin | 2 | 2022 | 695 | 0.210 |
Why?
|
| DNA-Binding Proteins | 5 | 2022 | 1224 | 0.210 |
Why?
|
| HEK293 Cells | 2 | 2024 | 615 | 0.210 |
Why?
|
| Lipid Metabolism | 1 | 2026 | 225 | 0.210 |
Why?
|
| Carbonated Beverages | 7 | 2002 | 21 | 0.210 |
Why?
|
| Renal Insufficiency | 3 | 1999 | 67 | 0.210 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 6 | 2005 | 39 | 0.210 |
Why?
|
| Administration, Oral | 8 | 2009 | 371 | 0.210 |
Why?
|
| Public Health Informatics | 1 | 2003 | 9 | 0.210 |
Why?
|
| Cocaine | 5 | 2000 | 101 | 0.210 |
Why?
|
| Prefrontal Cortex | 1 | 2025 | 127 | 0.210 |
Why?
|
| Fentanyl | 2 | 2022 | 66 | 0.200 |
Why?
|
| Dehydration | 1 | 2003 | 16 | 0.200 |
Why?
|
| Time Factors | 14 | 2025 | 3758 | 0.200 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2023 | 3 | 0.200 |
Why?
|
| Mice, Knockout | 4 | 2014 | 2152 | 0.200 |
Why?
|
| Autophagy | 1 | 2026 | 231 | 0.200 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 3 | 2020 | 9 | 0.200 |
Why?
|
| Biological Assay | 1 | 2023 | 56 | 0.200 |
Why?
|
| Asthma | 3 | 2002 | 483 | 0.200 |
Why?
|
| Proteolysis | 1 | 2024 | 154 | 0.200 |
Why?
|
| Inactivation, Metabolic | 2 | 2020 | 14 | 0.200 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2020 | 19 | 0.200 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 540 | 0.200 |
Why?
|
| Peritoneal Dialysis | 2 | 2016 | 13 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 250 | 0.190 |
Why?
|
| Mice, Transgenic | 4 | 2018 | 1287 | 0.190 |
Why?
|
| Xylazine | 1 | 2022 | 5 | 0.190 |
Why?
|
| Metabolome | 2 | 2020 | 36 | 0.190 |
Why?
|
| Cell Adhesion | 4 | 2001 | 218 | 0.190 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2020 | 34 | 0.190 |
Why?
|
| Hydrogen-Ion Concentration | 17 | 2002 | 463 | 0.190 |
Why?
|
| ErbB Receptors | 2 | 2019 | 127 | 0.190 |
Why?
|
| Calibration | 8 | 2020 | 67 | 0.190 |
Why?
|
| Neuroblastoma | 1 | 2022 | 54 | 0.190 |
Why?
|
| Integrin alpha6beta1 | 5 | 2013 | 34 | 0.190 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2022 | 17 | 0.180 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2000 | 102 | 0.180 |
Why?
|
| Kinetics | 17 | 1997 | 759 | 0.180 |
Why?
|
| Central Venous Catheters | 1 | 2022 | 17 | 0.180 |
Why?
|
| Therapeutic Equivalency | 7 | 2012 | 16 | 0.180 |
Why?
|
| Liver | 14 | 2018 | 868 | 0.180 |
Why?
|
| Fluorodeoxyglucose F18 | 7 | 2019 | 102 | 0.180 |
Why?
|
| Cross-Over Studies | 9 | 2012 | 164 | 0.180 |
Why?
|
| Blood Group Antigens | 1 | 2021 | 6 | 0.180 |
Why?
|
| Catheter-Related Infections | 1 | 2022 | 42 | 0.180 |
Why?
|
| Glucuronides | 5 | 2009 | 10 | 0.180 |
Why?
|
| Patient Selection | 1 | 2024 | 483 | 0.180 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 45 | 0.180 |
Why?
|
| Specimen Handling | 2 | 2021 | 61 | 0.180 |
Why?
|
| Tooth Diseases | 2 | 1995 | 5 | 0.180 |
Why?
|
| Myeloablative Agonists | 2 | 2012 | 12 | 0.180 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2015 | 80 | 0.180 |
Why?
|
| Transients and Migrants | 1 | 2022 | 26 | 0.180 |
Why?
|
| Predictive Value of Tests | 12 | 2020 | 1108 | 0.180 |
Why?
|
| Microglia | 3 | 2020 | 250 | 0.180 |
Why?
|
| Functional Neuroimaging | 1 | 2021 | 16 | 0.180 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2022 | 90 | 0.180 |
Why?
|
| Hyperlipidemias | 1 | 2001 | 34 | 0.170 |
Why?
|
| Hypolipidemic Agents | 1 | 2001 | 25 | 0.170 |
Why?
|
| Collagen | 3 | 2005 | 135 | 0.170 |
Why?
|
| Catheterization, Central Venous | 1 | 2022 | 84 | 0.170 |
Why?
|
| Eczema | 1 | 2021 | 9 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 6 | 2019 | 875 | 0.170 |
Why?
|
| Double-Blind Method | 5 | 2021 | 739 | 0.170 |
Why?
|
| Bacteremia | 1 | 2022 | 91 | 0.170 |
Why?
|
| Hypopigmentation | 1 | 2021 | 15 | 0.170 |
Why?
|
| Dermatitis, Atopic | 1 | 2021 | 28 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2010 | 352 | 0.170 |
Why?
|
| Nervous System Diseases | 1 | 2022 | 107 | 0.170 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2021 | 4 | 0.170 |
Why?
|
| Cocaine-Related Disorders | 3 | 2016 | 81 | 0.170 |
Why?
|
| Ethylene Glycol | 2 | 1998 | 10 | 0.170 |
Why?
|
| Neocortex | 1 | 2020 | 15 | 0.170 |
Why?
|
| Biomedical Research | 1 | 2023 | 260 | 0.170 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 242 | 0.170 |
Why?
|
| Cell Nucleus | 1 | 2024 | 630 | 0.170 |
Why?
|
| Drug Approval | 1 | 2021 | 28 | 0.160 |
Why?
|
| Perioperative Care | 1 | 2021 | 86 | 0.160 |
Why?
|
| Plasmalogens | 1 | 2020 | 1 | 0.160 |
Why?
|
| Dermatology | 1 | 2021 | 65 | 0.160 |
Why?
|
| Transcription Factors | 5 | 2015 | 1551 | 0.160 |
Why?
|
| Alkaline Phosphatase | 4 | 2019 | 46 | 0.160 |
Why?
|
| CRISPR-Cas Systems | 1 | 2024 | 368 | 0.160 |
Why?
|
| Citalopram | 1 | 2020 | 21 | 0.160 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2021 | 87 | 0.160 |
Why?
|
| Liver Function Tests | 2 | 2019 | 38 | 0.160 |
Why?
|
| Amino Acid Motifs | 3 | 2014 | 156 | 0.160 |
Why?
|
| Prevalence | 11 | 2024 | 1439 | 0.160 |
Why?
|
| Pandemics | 2 | 2022 | 672 | 0.160 |
Why?
|
| Isoenzymes | 7 | 1983 | 130 | 0.160 |
Why?
|
| Speech | 1 | 2021 | 60 | 0.160 |
Why?
|
| Acid Phosphatase | 4 | 1986 | 8 | 0.160 |
Why?
|
| Enzyme Activation | 4 | 2010 | 391 | 0.160 |
Why?
|
| Biological Availability | 8 | 2012 | 209 | 0.160 |
Why?
|
| Pancreas Transplantation | 2 | 1998 | 19 | 0.160 |
Why?
|
| Motor Disorders | 1 | 2020 | 4 | 0.160 |
Why?
|
| Blood | 1 | 2020 | 31 | 0.160 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2019 | 76 | 0.160 |
Why?
|
| Selenium | 1 | 2020 | 27 | 0.160 |
Why?
|
| Aphasia, Primary Progressive | 1 | 2020 | 1 | 0.160 |
Why?
|
| Paclitaxel | 2 | 2017 | 102 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 2 | 2021 | 428 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2014 | 234 | 0.160 |
Why?
|
| Receptors, Transferrin | 1 | 2019 | 33 | 0.150 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 27 | 0.150 |
Why?
|
| Inosine Monophosphate | 2 | 2008 | 3 | 0.150 |
Why?
|
| Executive Function | 1 | 2020 | 67 | 0.150 |
Why?
|
| Research | 1 | 2021 | 194 | 0.150 |
Why?
|
| Cytoprotection | 1 | 1999 | 18 | 0.150 |
Why?
|
| Protective Agents | 1 | 1999 | 12 | 0.150 |
Why?
|
| Vitiligo | 1 | 2021 | 120 | 0.150 |
Why?
|
| Antigens, Neoplasm | 2 | 2010 | 136 | 0.150 |
Why?
|
| Proteomics | 1 | 2021 | 292 | 0.150 |
Why?
|
| Dental Enamel | 8 | 2001 | 13 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2020 | 171 | 0.150 |
Why?
|
| Astrocytes | 1 | 2020 | 123 | 0.150 |
Why?
|
| Linear Models | 5 | 2025 | 405 | 0.140 |
Why?
|
| Genetic Testing | 1 | 2020 | 141 | 0.140 |
Why?
|
| Cerebral Palsy | 1 | 1998 | 21 | 0.140 |
Why?
|
| Survival Rate | 3 | 2019 | 843 | 0.140 |
Why?
|
| Encephalitis | 1 | 2019 | 37 | 0.140 |
Why?
|
| Transplantation Immunology | 1 | 1998 | 26 | 0.140 |
Why?
|
| Nuclear Proteins | 3 | 2015 | 790 | 0.140 |
Why?
|
| Drug Interactions | 6 | 2009 | 124 | 0.140 |
Why?
|
| Half-Life | 6 | 2012 | 81 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 1 | 2000 | 235 | 0.140 |
Why?
|
| Veterans | 2 | 2026 | 762 | 0.140 |
Why?
|
| Trans-Activators | 2 | 2013 | 320 | 0.140 |
Why?
|
| Algorithms | 3 | 2023 | 1044 | 0.140 |
Why?
|
| Xanthines | 1 | 1998 | 7 | 0.140 |
Why?
|
| Prostate | 4 | 1995 | 122 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2019 | 147 | 0.140 |
Why?
|
| Gene Knockout Techniques | 1 | 2018 | 96 | 0.140 |
Why?
|
| Lymphoma, T-Cell | 1 | 1998 | 22 | 0.140 |
Why?
|
| Radioimmunoassay | 8 | 2000 | 63 | 0.140 |
Why?
|
| Macrophages | 2 | 1994 | 1035 | 0.140 |
Why?
|
| Age Factors | 7 | 2025 | 1580 | 0.140 |
Why?
|
| Biological Psychiatry | 1 | 2017 | 2 | 0.140 |
Why?
|
| Cerebrovascular Circulation | 3 | 1995 | 183 | 0.140 |
Why?
|
| Cytoskeleton | 2 | 2017 | 140 | 0.130 |
Why?
|
| Milk Proteins | 1 | 1998 | 45 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.130 |
Why?
|
| Receptors, Laminin | 2 | 1996 | 17 | 0.130 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 1996 | 33 | 0.130 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 404 | 0.130 |
Why?
|
| Cardiovascular Diseases | 2 | 2022 | 861 | 0.130 |
Why?
|
| Statistics, Nonparametric | 8 | 2010 | 213 | 0.130 |
Why?
|
| Lactic Acid | 2 | 2014 | 75 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2018 | 184 | 0.130 |
Why?
|
| ROC Curve | 7 | 2022 | 292 | 0.130 |
Why?
|
| Extracellular Matrix | 2 | 2005 | 148 | 0.130 |
Why?
|
| Mutation, Missense | 1 | 2018 | 190 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2018 | 231 | 0.130 |
Why?
|
| Theophylline | 2 | 1990 | 8 | 0.130 |
Why?
|
| Fornix, Brain | 1 | 2016 | 11 | 0.130 |
Why?
|
| Machine Learning | 3 | 2024 | 192 | 0.130 |
Why?
|
| Analysis of Variance | 7 | 2002 | 602 | 0.130 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2017 | 37 | 0.130 |
Why?
|
| Caregivers | 1 | 2020 | 292 | 0.130 |
Why?
|
| Statistics as Topic | 4 | 2014 | 146 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 205 | 0.120 |
Why?
|
| Tubulin | 1 | 2017 | 73 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 2 | 1998 | 120 | 0.120 |
Why?
|
| Injections, Subcutaneous | 3 | 2021 | 70 | 0.120 |
Why?
|
| Nerve Degeneration | 3 | 2022 | 68 | 0.120 |
Why?
|
| Lactates | 1 | 1996 | 28 | 0.120 |
Why?
|
| Kidney Diseases | 5 | 2001 | 177 | 0.120 |
Why?
|
| Animals, Newborn | 3 | 1995 | 239 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 219 | 0.120 |
Why?
|
| Transfection | 6 | 2004 | 701 | 0.120 |
Why?
|
| Down-Regulation | 3 | 2014 | 324 | 0.120 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2017 | 76 | 0.120 |
Why?
|
| Neurons | 2 | 2020 | 933 | 0.120 |
Why?
|
| Mitochondria | 2 | 2020 | 401 | 0.120 |
Why?
|
| Anesthesia, Intravenous | 1 | 2016 | 13 | 0.120 |
Why?
|
| Anesthetics, Intravenous | 1 | 2016 | 25 | 0.120 |
Why?
|
| Cell Cycle | 2 | 2017 | 398 | 0.120 |
Why?
|
| Protease Inhibitors | 1 | 2017 | 106 | 0.120 |
Why?
|
| Cell Line | 5 | 2008 | 2021 | 0.120 |
Why?
|
| Antibodies | 3 | 2014 | 187 | 0.120 |
Why?
|
| Chemistry, Clinical | 3 | 1983 | 3 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2008 | 202 | 0.120 |
Why?
|
| Databases, Factual | 5 | 2024 | 881 | 0.120 |
Why?
|
| Organ Size | 3 | 2023 | 173 | 0.120 |
Why?
|
| Cigarette Smoking | 1 | 2016 | 56 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1995 | 37 | 0.120 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 86 | 0.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 15 | 0.120 |
Why?
|
| Health Personnel | 1 | 2020 | 384 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 401 | 0.110 |
Why?
|
| Immunity, Innate | 1 | 2021 | 819 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2021 | 544 | 0.110 |
Why?
|
| Clinical Enzyme Tests | 4 | 1998 | 13 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2020 | 476 | 0.110 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2015 | 82 | 0.110 |
Why?
|
| Class III Phosphatidylinositol 3-Kinases | 1 | 2015 | 5 | 0.110 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2015 | 9 | 0.110 |
Why?
|
| Pharmaceutical Vehicles | 2 | 2001 | 6 | 0.110 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2019 | 382 | 0.110 |
Why?
|
| DNA, Complementary | 4 | 2004 | 165 | 0.110 |
Why?
|
| Severity of Illness Index | 7 | 2021 | 1557 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2017 | 400 | 0.110 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 65 | 0.110 |
Why?
|
| Epidermal Growth Factor | 1 | 2015 | 49 | 0.110 |
Why?
|
| Metabolic Clearance Rate | 5 | 2012 | 49 | 0.110 |
Why?
|
| Everolimus | 3 | 2010 | 22 | 0.110 |
Why?
|
| Drug Administration Schedule | 5 | 2012 | 294 | 0.110 |
Why?
|
| Nootropic Agents | 1 | 2014 | 13 | 0.110 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 115 | 0.110 |
Why?
|
| England | 6 | 2002 | 28 | 0.110 |
Why?
|
| src-Family Kinases | 3 | 2009 | 64 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2016 | 319 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2014 | 33 | 0.110 |
Why?
|
| Integrin alpha6 | 1 | 2014 | 20 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 261 | 0.100 |
Why?
|
| Vidarabine | 2 | 2010 | 7 | 0.100 |
Why?
|
| Amino Acid Sequence | 3 | 2010 | 1589 | 0.100 |
Why?
|
| Living Donors | 3 | 2010 | 78 | 0.100 |
Why?
|
| Threonine | 2 | 2010 | 15 | 0.100 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2013 | 6 | 0.100 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2013 | 8 | 0.100 |
Why?
|
| Tissue Donors | 3 | 2010 | 146 | 0.100 |
Why?
|
| Apolipoproteins | 1 | 2013 | 14 | 0.100 |
Why?
|
| Thrombolytic Therapy | 1 | 1995 | 195 | 0.100 |
Why?
|
| Chromogranin A | 1 | 2013 | 8 | 0.100 |
Why?
|
| Genetic Variation | 4 | 2019 | 393 | 0.100 |
Why?
|
| Memory | 1 | 2014 | 123 | 0.100 |
Why?
|
| Leptin | 1 | 2014 | 88 | 0.100 |
Why?
|
| Indicators and Reagents | 8 | 2009 | 52 | 0.100 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2013 | 45 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 4 | 2006 | 3469 | 0.100 |
Why?
|
| Pilot Projects | 4 | 2010 | 1013 | 0.100 |
Why?
|
| Biological Transport | 1 | 2014 | 292 | 0.100 |
Why?
|
| Fruit | 5 | 2002 | 101 | 0.100 |
Why?
|
| Treatment Outcome | 7 | 2021 | 5776 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 60 | 0.100 |
Why?
|
| Base Sequence | 4 | 2004 | 1329 | 0.100 |
Why?
|
| Tissue Distribution | 5 | 2019 | 293 | 0.100 |
Why?
|
| Autocrine Communication | 1 | 2013 | 30 | 0.100 |
Why?
|
| Cytoplasm | 4 | 2002 | 282 | 0.100 |
Why?
|
| Myocardial Infarction | 4 | 1995 | 918 | 0.100 |
Why?
|
| RNA Splicing | 1 | 2014 | 166 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1255 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1998 | 630 | 0.100 |
Why?
|
| Age of Onset | 2 | 2026 | 173 | 0.090 |
Why?
|
| Polyenes | 1 | 1992 | 5 | 0.090 |
Why?
|
| Infusions, Intravenous | 4 | 2012 | 175 | 0.090 |
Why?
|
| Neuropilin-2 | 1 | 2013 | 40 | 0.090 |
Why?
|
| Young Adult | 8 | 2020 | 4793 | 0.090 |
Why?
|
| Gastrointestinal Agents | 1 | 2012 | 26 | 0.090 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2013 | 110 | 0.090 |
Why?
|
| Benzamides | 1 | 2012 | 67 | 0.090 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2012 | 17 | 0.090 |
Why?
|
| Capsules | 2 | 2009 | 33 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 440 | 0.090 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2012 | 8 | 0.090 |
Why?
|
| Morpholines | 1 | 2012 | 91 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 79 | 0.090 |
Why?
|
| Contrast Media | 2 | 2020 | 432 | 0.090 |
Why?
|
| Monitoring, Physiologic | 7 | 1997 | 162 | 0.090 |
Why?
|
| Feeding Behavior | 4 | 2002 | 263 | 0.090 |
Why?
|
| Regression Analysis | 5 | 2011 | 497 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 1655 | 0.090 |
Why?
|
| Dronabinol | 1 | 1991 | 31 | 0.090 |
Why?
|
| DNA | 2 | 1993 | 857 | 0.090 |
Why?
|
| Fluorescence Polarization Immunoassay | 4 | 2000 | 8 | 0.090 |
Why?
|
| Aspirin | 1 | 1992 | 171 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 4 | 2014 | 676 | 0.090 |
Why?
|
| Cadaver | 2 | 2010 | 127 | 0.090 |
Why?
|
| Colchicine | 1 | 1991 | 28 | 0.090 |
Why?
|
| Infant, Newborn | 5 | 2006 | 1416 | 0.090 |
Why?
|
| Amyloid | 2 | 2022 | 73 | 0.090 |
Why?
|
| Radiation Injuries, Experimental | 2 | 1988 | 9 | 0.090 |
Why?
|
| RNA, Messenger | 5 | 2009 | 1575 | 0.080 |
Why?
|
| Neurogranin | 2 | 2022 | 11 | 0.080 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2024 | 163 | 0.080 |
Why?
|
| Tea | 2 | 2001 | 32 | 0.080 |
Why?
|
| Neoplasm Grading | 1 | 2011 | 94 | 0.080 |
Why?
|
| Oral Hygiene | 2 | 2002 | 14 | 0.080 |
Why?
|
| Dinoprost | 2 | 2009 | 19 | 0.080 |
Why?
|
| src Homology Domains | 1 | 2010 | 21 | 0.080 |
Why?
|
| Diagnosis, Differential | 6 | 2009 | 988 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 158 | 0.080 |
Why?
|
| Physical Examination | 3 | 2000 | 109 | 0.080 |
Why?
|
| Mammary Glands, Human | 1 | 2011 | 56 | 0.080 |
Why?
|
| Intermediate Filaments | 2 | 2021 | 10 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 109 | 0.080 |
Why?
|
| Reagent Kits, Diagnostic | 4 | 2002 | 25 | 0.080 |
Why?
|
| Peptides | 1 | 2014 | 588 | 0.080 |
Why?
|
| Surveys and Questionnaires | 6 | 2024 | 2759 | 0.080 |
Why?
|
| Injections, Intravenous | 6 | 2005 | 159 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 2 | 2008 | 140 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 129 | 0.080 |
Why?
|
| Diagnostic Imaging | 2 | 2010 | 272 | 0.080 |
Why?
|
| Poisoning | 3 | 1999 | 27 | 0.080 |
Why?
|
| Glucosylceramidase | 2 | 2020 | 7 | 0.080 |
Why?
|
| Computer Simulation | 3 | 2025 | 483 | 0.080 |
Why?
|
| Thinness | 1 | 2010 | 43 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2009 | 9 | 0.080 |
Why?
|
| Pregnancy | 9 | 2009 | 2372 | 0.080 |
Why?
|
| Coronary Disease | 3 | 2000 | 246 | 0.080 |
Why?
|
| Cell Hypoxia | 1 | 2009 | 42 | 0.080 |
Why?
|
| S100 Proteins | 1 | 2009 | 20 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 414 | 0.080 |
Why?
|
| Nifedipine | 2 | 2002 | 18 | 0.080 |
Why?
|
| Citrates | 2 | 1995 | 19 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2009 | 125 | 0.080 |
Why?
|
| Calcineurin Inhibitors | 1 | 2009 | 22 | 0.070 |
Why?
|
| Alendronate | 1 | 2009 | 14 | 0.070 |
Why?
|
| Sample Size | 2 | 2025 | 66 | 0.070 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2009 | 10 | 0.070 |
Why?
|
| Anxiety | 1 | 2012 | 425 | 0.070 |
Why?
|
| Itraconazole | 1 | 2009 | 14 | 0.070 |
Why?
|
| Omeprazole | 1 | 2009 | 5 | 0.070 |
Why?
|
| Laboratories | 1 | 2009 | 27 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 4 | 2000 | 108 | 0.070 |
Why?
|
| Heterozygote | 2 | 2019 | 173 | 0.070 |
Why?
|
| Aerobiosis | 1 | 2008 | 8 | 0.070 |
Why?
|
| Colonic Neoplasms | 3 | 2002 | 220 | 0.070 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 45 | 0.070 |
Why?
|
| Magnetics | 1 | 2009 | 53 | 0.070 |
Why?
|
| Drug Stability | 3 | 2003 | 144 | 0.070 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2008 | 46 | 0.070 |
Why?
|
| Biopsy | 1 | 2010 | 454 | 0.070 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 47 | 0.070 |
Why?
|
| Diclofenac | 1 | 2008 | 5 | 0.070 |
Why?
|
| Mental Status Schedule | 3 | 2014 | 20 | 0.070 |
Why?
|
| Dental Plaque | 1 | 1988 | 5 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2012 | 211 | 0.070 |
Why?
|
| Substance-Related Disorders | 3 | 1999 | 750 | 0.070 |
Why?
|
| Drug Overdose | 3 | 1999 | 122 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2000 | 38 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2010 | 293 | 0.070 |
Why?
|
| Comorbidity | 3 | 2020 | 1113 | 0.070 |
Why?
|
| Cholinesterase Inhibitors | 1 | 1988 | 50 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2010 | 191 | 0.070 |
Why?
|
| Drug Tolerance | 1 | 2008 | 33 | 0.070 |
Why?
|
| Fatty Acid Desaturases | 3 | 1985 | 9 | 0.070 |
Why?
|
| Intestine, Small | 2 | 2004 | 82 | 0.070 |
Why?
|
| Insecticides | 1 | 1988 | 45 | 0.070 |
Why?
|
| Diet | 3 | 1999 | 533 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 2009 | 125 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2008 | 132 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2009 | 213 | 0.070 |
Why?
|
| Scotland | 2 | 2006 | 9 | 0.070 |
Why?
|
| Overweight | 1 | 2010 | 257 | 0.070 |
Why?
|
| DNA, Neoplasm | 2 | 2004 | 61 | 0.070 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2009 | 155 | 0.070 |
Why?
|
| Cell Division | 2 | 2000 | 449 | 0.070 |
Why?
|
| Blood Pressure | 4 | 2001 | 525 | 0.070 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2001 | 251 | 0.070 |
Why?
|
| Tablets | 4 | 2012 | 16 | 0.070 |
Why?
|
| Suicide, Attempted | 2 | 1999 | 111 | 0.070 |
Why?
|
| Chromatography, Gas | 2 | 1998 | 8 | 0.070 |
Why?
|
| Gadolinium | 1 | 2008 | 110 | 0.070 |
Why?
|
| Sudden Infant Death | 2 | 1985 | 28 | 0.060 |
Why?
|
| Memory Disorders | 3 | 2014 | 52 | 0.060 |
Why?
|
| Integrin beta4 | 1 | 2007 | 35 | 0.060 |
Why?
|
| Organ Specificity | 3 | 2002 | 198 | 0.060 |
Why?
|
| Citric Acid | 4 | 1998 | 20 | 0.060 |
Why?
|
| Antioxidants | 1 | 2009 | 249 | 0.060 |
Why?
|
| Periodontal Diseases | 1 | 1987 | 17 | 0.060 |
Why?
|
| Phenylpropionates | 1 | 2007 | 10 | 0.060 |
Why?
|
| Indians, North American | 1 | 1987 | 28 | 0.060 |
Why?
|
| Paroxetine | 1 | 2007 | 16 | 0.060 |
Why?
|
| United Kingdom | 3 | 2021 | 85 | 0.060 |
Why?
|
| Rats | 5 | 2016 | 1989 | 0.060 |
Why?
|
| Glutathione | 2 | 1994 | 55 | 0.060 |
Why?
|
| Myocardial Ischemia | 2 | 2000 | 117 | 0.060 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2007 | 30 | 0.060 |
Why?
|
| Synapses | 2 | 2022 | 193 | 0.060 |
Why?
|
| New Zealand | 3 | 2001 | 44 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 463 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 895 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2001 | 513 | 0.060 |
Why?
|
| Genetic Loci | 2 | 2017 | 116 | 0.060 |
Why?
|
| Body Fluids | 2 | 2020 | 20 | 0.060 |
Why?
|
| Endpoint Determination | 2 | 2023 | 27 | 0.060 |
Why?
|
| Diabetic Nephropathies | 2 | 1998 | 37 | 0.060 |
Why?
|
| Dental Enamel Solubility | 3 | 1998 | 3 | 0.060 |
Why?
|
| Apoptosis | 4 | 2004 | 1100 | 0.060 |
Why?
|
| Phenytoin | 1 | 1986 | 15 | 0.060 |
Why?
|
| Fluorides | 3 | 2001 | 29 | 0.060 |
Why?
|
| Intestinal Absorption | 1 | 2006 | 32 | 0.060 |
Why?
|
| Plasma Exchange | 1 | 1986 | 24 | 0.060 |
Why?
|
| Sex Factors | 4 | 2020 | 991 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 592 | 0.060 |
Why?
|
| Quality Control | 3 | 2012 | 78 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 907 | 0.060 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2006 | 83 | 0.060 |
Why?
|
| Verapamil | 1 | 2005 | 6 | 0.060 |
Why?
|
| Mice, Nude | 3 | 2020 | 287 | 0.060 |
Why?
|
| Disopyramide | 1 | 1985 | 11 | 0.060 |
Why?
|
| 1-Propanol | 1 | 1985 | 3 | 0.060 |
Why?
|
| Body Surface Area | 1 | 2025 | 11 | 0.060 |
Why?
|
| Embryonic and Fetal Development | 2 | 1996 | 46 | 0.060 |
Why?
|
| Culture Media, Conditioned | 1 | 2005 | 52 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2005 | 34 | 0.060 |
Why?
|
| Hepacivirus | 1 | 2006 | 134 | 0.050 |
Why?
|
| Creatinine | 4 | 2009 | 135 | 0.050 |
Why?
|
| 3T3 Cells | 1 | 2005 | 111 | 0.050 |
Why?
|
| Hematologic Tests | 1 | 2024 | 16 | 0.050 |
Why?
|
| Fertility | 2 | 1996 | 84 | 0.050 |
Why?
|
| Biotransformation | 3 | 2009 | 24 | 0.050 |
Why?
|
| Durapatite | 2 | 2001 | 27 | 0.050 |
Why?
|
| Sheep | 2 | 1996 | 189 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 2004 | 197 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2005 | 166 | 0.050 |
Why?
|
| Lewy Bodies | 1 | 2024 | 3 | 0.050 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 33 | 0.050 |
Why?
|
| Neurofibrillary Tangles | 1 | 2024 | 11 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2025 | 195 | 0.050 |
Why?
|
| China | 1 | 2025 | 175 | 0.050 |
Why?
|
| Radiopharmaceuticals | 2 | 2018 | 196 | 0.050 |
Why?
|
| Public Health | 1 | 2006 | 186 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2008 | 718 | 0.050 |
Why?
|
| Substrate Specificity | 5 | 1998 | 341 | 0.050 |
Why?
|
| Graft Survival | 3 | 2012 | 296 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2006 | 325 | 0.050 |
Why?
|
| Gestational Age | 3 | 2000 | 192 | 0.050 |
Why?
|
| Spectrophotometry | 3 | 2013 | 30 | 0.050 |
Why?
|
| Toothbrushing | 2 | 2002 | 3 | 0.050 |
Why?
|
| Huntington Disease | 1 | 2025 | 159 | 0.050 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2004 | 18 | 0.050 |
Why?
|
| Counseling | 2 | 1999 | 375 | 0.050 |
Why?
|
| Integrin beta1 | 1 | 2004 | 32 | 0.050 |
Why?
|
| Prednisone | 2 | 1997 | 83 | 0.050 |
Why?
|
| Cross Reactions | 4 | 2008 | 139 | 0.050 |
Why?
|
| Abortion, Spontaneous | 1 | 2003 | 30 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2005 | 195 | 0.050 |
Why?
|
| Bilirubin | 3 | 2019 | 19 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2003 | 102 | 0.050 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2004 | 81 | 0.050 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2023 | 15 | 0.050 |
Why?
|
| Mathematics | 4 | 1986 | 34 | 0.050 |
Why?
|
| Clusterin | 1 | 2022 | 4 | 0.050 |
Why?
|
| Apolipoprotein A-I | 1 | 2022 | 23 | 0.050 |
Why?
|
| Gingiva | 1 | 2002 | 8 | 0.050 |
Why?
|
| Endocytosis | 1 | 2004 | 152 | 0.050 |
Why?
|
| False Positive Reactions | 3 | 1999 | 77 | 0.050 |
Why?
|
| GAP-43 Protein | 1 | 2022 | 2 | 0.050 |
Why?
|
| High-Throughput Screening Assays | 1 | 2023 | 79 | 0.050 |
Why?
|
| Deoxyguanine Nucleotides | 1 | 2002 | 3 | 0.050 |
Why?
|
| Dideoxynucleosides | 1 | 2002 | 9 | 0.050 |
Why?
|
| Bronchodilator Agents | 2 | 2002 | 121 | 0.050 |
Why?
|
| Ethanol | 3 | 1996 | 329 | 0.050 |
Why?
|
| NAD | 2 | 2008 | 53 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2019 | 204 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2002 | 58 | 0.050 |
Why?
|
| Lectins | 2 | 1979 | 43 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 22 | 0.050 |
Why?
|
| Kidney Function Tests | 3 | 2009 | 36 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2022 | 29 | 0.050 |
Why?
|
| Lymphokines | 1 | 2002 | 67 | 0.050 |
Why?
|
| Community Participation | 1 | 2022 | 48 | 0.050 |
Why?
|
| Peptide Initiation Factors | 1 | 2002 | 37 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 585 | 0.050 |
Why?
|
| Feminism | 1 | 2022 | 2 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 2 | 2019 | 35 | 0.050 |
Why?
|
| Mexican Americans | 1 | 2022 | 14 | 0.040 |
Why?
|
| Prostatic Diseases | 1 | 1982 | 9 | 0.040 |
Why?
|
| Alanine Transaminase | 2 | 2019 | 46 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2022 | 67 | 0.040 |
Why?
|
| Violence | 1 | 2003 | 171 | 0.040 |
Why?
|
| Medical History Taking | 2 | 1993 | 65 | 0.040 |
Why?
|
| Farmers | 1 | 2022 | 20 | 0.040 |
Why?
|
| Body Constitution | 1 | 2001 | 16 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2002 | 129 | 0.040 |
Why?
|
| Mineral Waters | 1 | 2001 | 1 | 0.040 |
Why?
|
| Saliva, Artificial | 1 | 2001 | 2 | 0.040 |
Why?
|
| Dermatologists | 1 | 2021 | 11 | 0.040 |
Why?
|
| Gastric Mucosa | 1 | 2001 | 53 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 2001 | 77 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2002 | 94 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2001 | 71 | 0.040 |
Why?
|
| United States | 2 | 2025 | 8085 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 139 | 0.040 |
Why?
|
| Diet, Vegetarian | 1 | 2001 | 5 | 0.040 |
Why?
|
| Dialysis | 2 | 1995 | 8 | 0.040 |
Why?
|
| Ultrafiltration | 2 | 1995 | 10 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2001 | 104 | 0.040 |
Why?
|
| Helicobacter pylori | 1 | 2001 | 58 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2001 | 202 | 0.040 |
Why?
|
| Primary Progressive Nonfluent Aphasia | 1 | 2021 | 1 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2002 | 266 | 0.040 |
Why?
|
| Shock, Hemorrhagic | 1 | 2001 | 18 | 0.040 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2000 | 3 | 0.040 |
Why?
|
| Language Tests | 1 | 2021 | 39 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 2 | 2009 | 120 | 0.040 |
Why?
|
| Temperature | 4 | 1985 | 314 | 0.040 |
Why?
|
| Language | 1 | 2022 | 154 | 0.040 |
Why?
|
| Health Priorities | 1 | 2001 | 29 | 0.040 |
Why?
|
| Solutions | 3 | 2007 | 63 | 0.040 |
Why?
|
| Molecular Structure | 2 | 2009 | 316 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 793 | 0.040 |
Why?
|
| Cotinine | 1 | 2000 | 20 | 0.040 |
Why?
|
| Thiazoles | 2 | 2011 | 45 | 0.040 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2020 | 6 | 0.040 |
Why?
|
| Duodenum | 1 | 1980 | 41 | 0.040 |
Why?
|
| Antigens, Bacterial | 1 | 2001 | 200 | 0.040 |
Why?
|
| Infertility | 1 | 2001 | 30 | 0.040 |
Why?
|
| Marijuana Abuse | 1 | 2000 | 23 | 0.040 |
Why?
|
| Phosphotransferases | 1 | 2020 | 22 | 0.040 |
Why?
|
| Selenocysteine | 1 | 2020 | 15 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 72 | 0.040 |
Why?
|
| Life Style | 2 | 2001 | 321 | 0.040 |
Why?
|
| Selenium Compounds | 1 | 2020 | 30 | 0.040 |
Why?
|
| Dental Occlusion, Traumatic | 1 | 2000 | 1 | 0.040 |
Why?
|
| Heart Rate | 2 | 2001 | 331 | 0.040 |
Why?
|
| Health Surveys | 1 | 2001 | 317 | 0.040 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2000 | 5 | 0.040 |
Why?
|
| Radionuclide Angiography | 1 | 2000 | 1 | 0.040 |
Why?
|
| Cannabinoids | 1 | 2000 | 41 | 0.040 |
Why?
|
| Albuterol | 1 | 2000 | 24 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2003 | 354 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 1993 | 1979 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 1991 | 135 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 1629 | 0.040 |
Why?
|
| Liver Failure | 1 | 1999 | 18 | 0.040 |
Why?
|
| Pancreas | 1 | 1980 | 154 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2021 | 207 | 0.040 |
Why?
|
| Hair | 1 | 2000 | 81 | 0.040 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2000 | 94 | 0.040 |
Why?
|
| North America | 1 | 2020 | 113 | 0.040 |
Why?
|
| Computer-Assisted Instruction | 1 | 2000 | 80 | 0.040 |
Why?
|
| Polyethylene Glycols | 2 | 1993 | 173 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 203 | 0.040 |
Why?
|
| Leucine | 1 | 2020 | 65 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2000 | 78 | 0.040 |
Why?
|
| Domestic Violence | 1 | 1999 | 40 | 0.040 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2019 | 4 | 0.040 |
Why?
|
| Drug Contamination | 1 | 1999 | 11 | 0.040 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2000 | 62 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 1005 | 0.040 |
Why?
|
| Sparteine | 1 | 1999 | 1 | 0.040 |
Why?
|
| Leukopenia | 1 | 1999 | 16 | 0.040 |
Why?
|
| Creatine Kinase | 2 | 1978 | 42 | 0.040 |
Why?
|
| Olfaction Disorders | 1 | 2019 | 15 | 0.040 |
Why?
|
| Fabaceae | 1 | 1999 | 10 | 0.040 |
Why?
|
| Triage | 1 | 2001 | 134 | 0.040 |
Why?
|
| Plants, Medicinal | 1 | 1999 | 19 | 0.040 |
Why?
|
| Nicotine | 1 | 2000 | 118 | 0.040 |
Why?
|
| Neurocalcin | 1 | 2019 | 1 | 0.040 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2000 | 49 | 0.040 |
Why?
|
| Health Services Research | 1 | 2000 | 265 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2019 | 48 | 0.040 |
Why?
|
| Cardiac Catheterization | 3 | 2000 | 292 | 0.040 |
Why?
|
| Cholinergic Antagonists | 1 | 1999 | 32 | 0.040 |
Why?
|
| Seeds | 1 | 1999 | 29 | 0.040 |
Why?
|
| Synaptosomal-Associated Protein 25 | 1 | 2019 | 10 | 0.040 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2019 | 14 | 0.040 |
Why?
|
| Parkinsonian Disorders | 1 | 2019 | 15 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 432 | 0.040 |
Why?
|
| Azathioprine | 3 | 1997 | 27 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 1999 | 55 | 0.040 |
Why?
|
| Motor Neuron Disease | 1 | 2019 | 28 | 0.040 |
Why?
|
| Phytotherapy | 1 | 1999 | 34 | 0.040 |
Why?
|
| Bruxism | 1 | 1998 | 1 | 0.040 |
Why?
|
| Tooth Attrition | 1 | 1998 | 1 | 0.040 |
Why?
|
| Gastric Acidity Determination | 1 | 1998 | 4 | 0.040 |
Why?
|
| Dental Care for Chronically Ill | 1 | 1998 | 4 | 0.040 |
Why?
|
| Korea | 2 | 2009 | 8 | 0.040 |
Why?
|
| Citrus | 3 | 2001 | 46 | 0.040 |
Why?
|
| Multiple System Atrophy | 1 | 2018 | 13 | 0.040 |
Why?
|
| Incisor | 2 | 1997 | 7 | 0.040 |
Why?
|
| Halothane | 2 | 1976 | 3 | 0.040 |
Why?
|
| Fatty Acid Binding Protein 3 | 1 | 2018 | 4 | 0.040 |
Why?
|
| Chi-Square Distribution | 4 | 2001 | 414 | 0.040 |
Why?
|
| Urban Population | 1 | 1999 | 200 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 361 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 1999 | 102 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1998 | 44 | 0.040 |
Why?
|
| Chloramphenicol | 1 | 1998 | 6 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2000 | 198 | 0.040 |
Why?
|
| Acetaminophen | 1 | 1999 | 52 | 0.040 |
Why?
|
| Tooth, Deciduous | 2 | 1995 | 2 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 622 | 0.030 |
Why?
|
| Janus Kinase 3 | 1 | 1998 | 4 | 0.030 |
Why?
|
| Automation, Laboratory | 1 | 2018 | 9 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 1998 | 14 | 0.030 |
Why?
|
| Proportional Hazards Models | 3 | 2009 | 739 | 0.030 |
Why?
|
| Lethal Dose 50 | 1 | 1998 | 16 | 0.030 |
Why?
|
| Angina Pectoris | 2 | 1995 | 35 | 0.030 |
Why?
|
| Swine | 3 | 1995 | 394 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 1997 | 10 | 0.030 |
Why?
|
| Calcium Oxalate | 1 | 1998 | 12 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 1998 | 15 | 0.030 |
Why?
|
| Lithium | 1 | 1998 | 22 | 0.030 |
Why?
|
| rac GTP-Binding Proteins | 1 | 1997 | 16 | 0.030 |
Why?
|
| Vomiting | 1 | 1999 | 139 | 0.030 |
Why?
|
| Acidosis | 1 | 1998 | 28 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2012 | 236 | 0.030 |
Why?
|
| Androstadienes | 1 | 1997 | 43 | 0.030 |
Why?
|
| Heart | 1 | 2000 | 297 | 0.030 |
Why?
|
| Kidney Calculi | 1 | 1998 | 34 | 0.030 |
Why?
|
| Dysbiosis | 1 | 2018 | 74 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2018 | 164 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2010 | 576 | 0.030 |
Why?
|
| Buffers | 3 | 2002 | 22 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 1997 | 94 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2014 | 354 | 0.030 |
Why?
|
| Histocytochemistry | 2 | 1991 | 47 | 0.030 |
Why?
|
| Endophenotypes | 1 | 2017 | 9 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2018 | 136 | 0.030 |
Why?
|
| Xanthine | 1 | 1997 | 2 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2000 | 316 | 0.030 |
Why?
|
| Ribonucleotides | 1 | 1997 | 19 | 0.030 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2009 | 91 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 1997 | 54 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 1999 | 250 | 0.030 |
Why?
|
| HIV-1 | 1 | 2002 | 706 | 0.030 |
Why?
|
| Gonadotropins, Pituitary | 1 | 1996 | 3 | 0.030 |
Why?
|
| Prostatic Neoplasms | 2 | 1995 | 493 | 0.030 |
Why?
|
| Vasoconstriction | 2 | 1993 | 22 | 0.030 |
Why?
|
| Internet | 1 | 2000 | 466 | 0.030 |
Why?
|
| Dialysis Solutions | 1 | 2016 | 7 | 0.030 |
Why?
|
| Carcinoma | 1 | 1997 | 130 | 0.030 |
Why?
|
| Epitopes | 1 | 1997 | 291 | 0.030 |
Why?
|
| NFATC Transcription Factors | 2 | 2009 | 20 | 0.030 |
Why?
|
| Tooth Abrasion | 1 | 1996 | 1 | 0.030 |
Why?
|
| Bromides | 2 | 1976 | 2 | 0.030 |
Why?
|
| Liver Diseases | 3 | 1997 | 158 | 0.030 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2016 | 8 | 0.030 |
Why?
|
| Anesthesia, Inhalation | 2 | 1976 | 14 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2012 | 754 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 2 | 1994 | 140 | 0.030 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 1996 | 26 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2019 | 791 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 2016 | 67 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2001 | 739 | 0.030 |
Why?
|
| Testosterone | 1 | 1996 | 128 | 0.030 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2015 | 7 | 0.030 |
Why?
|
| Calcium | 2 | 2001 | 581 | 0.030 |
Why?
|
| Catheterization | 1 | 2016 | 111 | 0.030 |
Why?
|
| Digestive System | 2 | 2002 | 26 | 0.030 |
Why?
|
| Hydrolysis | 3 | 1988 | 147 | 0.030 |
Why?
|
| Repressor Proteins | 2 | 2013 | 351 | 0.030 |
Why?
|
| Logistic Models | 4 | 2001 | 1270 | 0.030 |
Why?
|
| Testis | 1 | 1996 | 160 | 0.030 |
Why?
|
| Orosomucoid | 1 | 1995 | 1 | 0.030 |
Why?
|
| Sodium Salicylate | 1 | 1995 | 3 | 0.030 |
Why?
|
| Phytohemagglutinins | 1 | 1995 | 15 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 1998 | 286 | 0.030 |
Why?
|
| Smoking | 1 | 2000 | 861 | 0.030 |
Why?
|
| Radionuclide Ventriculography | 1 | 1995 | 5 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2007 | 42 | 0.030 |
Why?
|
| Furosemide | 1 | 1995 | 19 | 0.030 |
Why?
|
| Rest | 1 | 1995 | 45 | 0.030 |
Why?
|
| Drinking Behavior | 1 | 1995 | 9 | 0.030 |
Why?
|
| Tooth Discoloration | 1 | 1995 | 1 | 0.030 |
Why?
|
| Tooth Eruption | 1 | 1995 | 1 | 0.030 |
Why?
|
| Gingival Hyperplasia | 1 | 1995 | 3 | 0.030 |
Why?
|
| Dental Enamel Hypoplasia | 1 | 1995 | 2 | 0.030 |
Why?
|
| Biliary Atresia | 1 | 1995 | 2 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 267 | 0.030 |
Why?
|
| Fluorine Radioisotopes | 1 | 2014 | 8 | 0.030 |
Why?
|
| Barbiturates | 1 | 1995 | 6 | 0.030 |
Why?
|
| Physical Exertion | 1 | 1995 | 80 | 0.030 |
Why?
|
| Philadelphia | 3 | 1999 | 24 | 0.030 |
Why?
|
| Cysteamine | 1 | 1994 | 3 | 0.030 |
Why?
|
| Cost Control | 2 | 1993 | 24 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 1995 | 70 | 0.030 |
Why?
|
| Rectum | 1 | 1995 | 96 | 0.030 |
Why?
|
| Trefoil Factor-3 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Albuminuria | 1 | 1994 | 28 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 710 | 0.030 |
Why?
|
| Cystatin C | 1 | 2014 | 9 | 0.030 |
Why?
|
| Bone Marrow Purging | 1 | 1994 | 2 | 0.030 |
Why?
|
| In Vitro Techniques | 3 | 2000 | 491 | 0.030 |
Why?
|
| Morphine | 1 | 1995 | 60 | 0.030 |
Why?
|
| Cerebral Ventricles | 1 | 2014 | 29 | 0.030 |
Why?
|
| Disulfides | 1 | 1994 | 67 | 0.030 |
Why?
|
| Manganese | 1 | 1994 | 20 | 0.030 |
Why?
|
| Hydroxybutyrate Dehydrogenase | 1 | 1974 | 1 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2014 | 18 | 0.030 |
Why?
|
| Lidocaine | 2 | 1984 | 33 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1995 | 171 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2014 | 35 | 0.030 |
Why?
|
| Exercise | 1 | 2001 | 961 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1995 | 247 | 0.030 |
Why?
|
| Carbon Dioxide | 3 | 2001 | 81 | 0.030 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2014 | 31 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2007 | 500 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 120 | 0.030 |
Why?
|
| Proteins | 1 | 2000 | 764 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 1994 | 84 | 0.030 |
Why?
|
| Bulimia | 1 | 1994 | 17 | 0.030 |
Why?
|
| Oral Health | 1 | 1995 | 64 | 0.030 |
Why?
|
| Dipyridamole | 1 | 1994 | 17 | 0.030 |
Why?
|
| Pharmacology, Clinical | 1 | 1993 | 3 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 128 | 0.030 |
Why?
|
| Blood Specimen Collection | 2 | 1983 | 20 | 0.030 |
Why?
|
| Erythrocyte Count | 1 | 2013 | 15 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2009 | 801 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 1999 | 555 | 0.030 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1994 | 34 | 0.030 |
Why?
|
| Societies, Scientific | 2 | 1983 | 36 | 0.030 |
Why?
|
| Respiration | 2 | 1984 | 93 | 0.030 |
Why?
|
| Methanol | 1 | 1993 | 10 | 0.030 |
Why?
|
| Complement C3b Inactivator Proteins | 1 | 2013 | 4 | 0.030 |
Why?
|
| Sweden | 1 | 2013 | 64 | 0.030 |
Why?
|
| Cell Communication | 1 | 1994 | 133 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1996 | 325 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 62 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2013 | 17 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 12 | 0.020 |
Why?
|
| Perfusion | 1 | 1993 | 75 | 0.020 |
Why?
|
| Autoanalysis | 2 | 2007 | 2 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2013 | 11 | 0.020 |
Why?
|
| Coronary Angiography | 3 | 2000 | 210 | 0.020 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2013 | 31 | 0.020 |
Why?
|
| Trichotillomania | 1 | 1993 | 11 | 0.020 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1993 | 36 | 0.020 |
Why?
|
| Micelles | 1 | 1993 | 84 | 0.020 |
Why?
|
| Chickens | 1 | 1993 | 94 | 0.020 |
Why?
|
| Gingival Crevicular Fluid | 1 | 1992 | 1 | 0.020 |
Why?
|
| Hypophosphatasia | 1 | 1992 | 1 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1994 | 869 | 0.020 |
Why?
|
| Serine | 1 | 2013 | 90 | 0.020 |
Why?
|
| Macrophage Activation | 1 | 1993 | 115 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 3 | 2006 | 735 | 0.020 |
Why?
|
| Irritable Mood | 1 | 2012 | 16 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1993 | 364 | 0.020 |
Why?
|
| Apathy | 1 | 2012 | 9 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 1998 | 642 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 1993 | 384 | 0.020 |
Why?
|
| Heart Failure | 1 | 2000 | 948 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2013 | 117 | 0.020 |
Why?
|
| Observer Variation | 3 | 2001 | 216 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 1993 | 178 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 542 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 242 | 0.020 |
Why?
|
| Inflammation | 1 | 2019 | 1186 | 0.020 |
Why?
|
| Adenocarcinoma | 2 | 2003 | 364 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 795 | 0.020 |
Why?
|
| Multivariate Analysis | 3 | 1999 | 929 | 0.020 |
Why?
|
| Fetal Blood | 3 | 1997 | 73 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 526 | 0.020 |
Why?
|
| Antibody Specificity | 2 | 2008 | 102 | 0.020 |
Why?
|
| Connective Tissue | 1 | 1991 | 11 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 1991 | 68 | 0.020 |
Why?
|
| Death | 1 | 1991 | 33 | 0.020 |
Why?
|
| Cartilage | 1 | 1991 | 35 | 0.020 |
Why?
|
| Sampling Studies | 2 | 2001 | 65 | 0.020 |
Why?
|
| Solubility | 2 | 2001 | 192 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2010 | 47 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2010 | 23 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2010 | 11 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 26 | 0.020 |
Why?
|
| Transplantation Chimera | 1 | 2010 | 40 | 0.020 |
Why?
|
| Research Design | 1 | 1993 | 585 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1995 | 496 | 0.020 |
Why?
|
| Heart-Lung Transplantation | 1 | 1990 | 7 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 447 | 0.020 |
Why?
|
| Canada | 1 | 1990 | 153 | 0.020 |
Why?
|
| Secretory Rate | 2 | 2002 | 10 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2010 | 99 | 0.020 |
Why?
|
| Enterohepatic Circulation | 1 | 2009 | 1 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2010 | 135 | 0.020 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2009 | 3 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2001 | 213 | 0.020 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2009 | 1 | 0.020 |
Why?
|
| F2-Isoprostanes | 1 | 2009 | 5 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 113 | 0.020 |
Why?
|
| Catalase | 1 | 2009 | 21 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2009 | 28 | 0.020 |
Why?
|
| Callithrix | 1 | 2009 | 21 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 11 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 1231 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2009 | 9 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 655 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 1990 | 126 | 0.020 |
Why?
|
| Propoxur | 1 | 1988 | 1 | 0.020 |
Why?
|
| Plasma | 1 | 2009 | 38 | 0.020 |
Why?
|
| Butyrylcholinesterase | 1 | 1988 | 3 | 0.020 |
Why?
|
| Neoplasm Transplantation | 2 | 2000 | 168 | 0.020 |
Why?
|
| Fasting | 1 | 2009 | 52 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2009 | 36 | 0.020 |
Why?
|
| Chemistry | 1 | 1988 | 31 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2009 | 373 | 0.020 |
Why?
|
| Aorta | 1 | 2009 | 108 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1988 | 96 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 1990 | 252 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 198 | 0.020 |
Why?
|
| Hematopoietic System | 1 | 1988 | 10 | 0.020 |
Why?
|
| Body Temperature | 1 | 1988 | 44 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1988 | 26 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 84 | 0.020 |
Why?
|
| Acyl-CoA Dehydrogenase | 2 | 1985 | 10 | 0.020 |
Why?
|
| Receptor, trkB | 1 | 2007 | 7 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2009 | 221 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1988 | 77 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 42 | 0.020 |
Why?
|
| Fibrosis | 1 | 2008 | 172 | 0.020 |
Why?
|
| Lymphoma | 1 | 2008 | 101 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1994 | 731 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2007 | 46 | 0.020 |
Why?
|
| DMF Index | 1 | 1987 | 3 | 0.020 |
Why?
|
| Malocclusion | 1 | 1987 | 3 | 0.020 |
Why?
|
| Quebec | 1 | 1987 | 15 | 0.020 |
Why?
|
| Gingivitis | 1 | 1987 | 8 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 1988 | 66 | 0.020 |
Why?
|
| Social Class | 2 | 2001 | 137 | 0.020 |
Why?
|
| Atmospheric Pressure | 1 | 2007 | 3 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2008 | 80 | 0.020 |
Why?
|
| Fatty Acids | 2 | 1985 | 197 | 0.020 |
Why?
|
| Dental Caries | 1 | 1987 | 30 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 261 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 156 | 0.020 |
Why?
|
| Adrenal Glands | 2 | 1996 | 34 | 0.020 |
Why?
|
| Antigens | 1 | 1986 | 145 | 0.020 |
Why?
|
| Osteoarthritis | 1 | 2008 | 146 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 2005 | 7 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 2 | 1986 | 35 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 1986 | 17 | 0.010 |
Why?
|
| Methods | 2 | 1977 | 40 | 0.010 |
Why?
|
| Depression | 1 | 2012 | 899 | 0.010 |
Why?
|
| Metabolism, Inborn Errors | 1 | 1985 | 20 | 0.010 |
Why?
|
| Pain | 1 | 2008 | 398 | 0.010 |
Why?
|
| Litter Size | 2 | 1996 | 9 | 0.010 |
Why?
|
| Acetone | 1 | 1985 | 5 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 2 | 1996 | 86 | 0.010 |
Why?
|
| Seizures | 1 | 1986 | 140 | 0.010 |
Why?
|
| Luteinizing Hormone | 2 | 1996 | 101 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1984 | 16 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 30 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2004 | 24 | 0.010 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2004 | 51 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2004 | 27 | 0.010 |
Why?
|
| Chemotaxis | 1 | 2004 | 50 | 0.010 |
Why?
|
| Receptors, CXCR3 | 1 | 2004 | 35 | 0.010 |
Why?
|
| Reye Syndrome | 1 | 1984 | 1 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2004 | 43 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2004 | 109 | 0.010 |
Why?
|
| Chemokine CXCL10 | 1 | 2004 | 56 | 0.010 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 1984 | 13 | 0.010 |
Why?
|
| Semen | 1 | 1984 | 50 | 0.010 |
Why?
|
| Cell Surface Extensions | 1 | 2004 | 6 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 2004 | 18 | 0.010 |
Why?
|
| Glutarates | 1 | 1984 | 11 | 0.010 |
Why?
|
| Muscles | 2 | 1976 | 179 | 0.010 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2003 | 2 | 0.010 |
Why?
|
| Sp1 Transcription Factor | 1 | 2003 | 21 | 0.010 |
Why?
|
| Pharmacokinetics | 1 | 2003 | 7 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2003 | 19 | 0.010 |
Why?
|
| Prisoners | 1 | 2006 | 179 | 0.010 |
Why?
|
| Behavior | 1 | 2003 | 36 | 0.010 |
Why?
|
| Bone Diseases | 1 | 1983 | 25 | 0.010 |
Why?
|
| Hypoxia | 1 | 1984 | 119 | 0.010 |
Why?
|
| Feedback | 1 | 2003 | 91 | 0.010 |
Why?
|
| Prenatal Diagnosis | 1 | 1984 | 40 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2004 | 169 | 0.010 |
Why?
|
| Sexual Partners | 1 | 2003 | 76 | 0.010 |
Why?
|
| Placenta | 1 | 1983 | 67 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 610 | 0.010 |
Why?
|
| Catalysis | 1 | 1983 | 163 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2005 | 182 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2004 | 163 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1991 | 105 | 0.010 |
Why?
|
| Periodontal Index | 1 | 2002 | 4 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1985 | 222 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 22 | 0.010 |
Why?
|
| Amino Acids | 1 | 1983 | 148 | 0.010 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2002 | 15 | 0.010 |
Why?
|
| Polyribosomes | 1 | 2002 | 16 | 0.010 |
Why?
|
| Dental Devices, Home Care | 1 | 2002 | 1 | 0.010 |
Why?
|
| Toothpastes | 1 | 2002 | 2 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 92 | 0.010 |
Why?
|
| Mouthwashes | 1 | 2002 | 5 | 0.010 |
Why?
|
| Reagent Strips | 1 | 2002 | 5 | 0.010 |
Why?
|
| Dental Care | 1 | 2002 | 6 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2002 | 116 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1983 | 152 | 0.010 |
Why?
|
| Digestive System Diseases | 1 | 2002 | 14 | 0.010 |
Why?
|
| Actins | 1 | 2004 | 263 | 0.010 |
Why?
|
| Viremia | 1 | 2002 | 46 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 2002 | 54 | 0.010 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2002 | 43 | 0.010 |
Why?
|
| RNA, Bacterial | 1 | 2002 | 73 | 0.010 |
Why?
|
| Tyrphostins | 1 | 2001 | 3 | 0.010 |
Why?
|
| Immunodiffusion | 1 | 1981 | 5 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2002 | 68 | 0.010 |
Why?
|
| Quinazolines | 1 | 2001 | 21 | 0.010 |
Why?
|
| Apatites | 1 | 2001 | 3 | 0.010 |
Why?
|
| Puberty | 1 | 1982 | 59 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2002 | 168 | 0.010 |
Why?
|
| Phosphorus | 1 | 2001 | 16 | 0.010 |
Why?
|
| Sulfates | 1 | 2001 | 14 | 0.010 |
Why?
|
| Minerals | 1 | 2001 | 20 | 0.010 |
Why?
|
| Dogs | 1 | 2002 | 315 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2001 | 95 | 0.010 |
Why?
|
| Dentin | 1 | 2001 | 5 | 0.010 |
Why?
|
| Aerosols | 1 | 2001 | 46 | 0.010 |
Why?
|
| Alcoholic Beverages | 1 | 2001 | 7 | 0.010 |
Why?
|
| Dental Deposits | 1 | 2001 | 1 | 0.010 |
Why?
|
| Dental Pellicle | 1 | 2001 | 1 | 0.010 |
Why?
|
| Magnesium | 1 | 2001 | 54 | 0.010 |
Why?
|
| Government Agencies | 1 | 2001 | 11 | 0.010 |
Why?
|
| Materials Testing | 1 | 2001 | 88 | 0.010 |
Why?
|
| Drug Resistance, Viral | 1 | 2002 | 160 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2001 | 96 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2002 | 153 | 0.010 |
Why?
|
| Financing, Government | 1 | 2001 | 31 | 0.010 |
Why?
|
| Textbooks as Topic | 1 | 2000 | 2 | 0.010 |
Why?
|
| Education, Dental | 1 | 2000 | 5 | 0.010 |
Why?
|
| Tape Recording | 1 | 2000 | 13 | 0.010 |
Why?
|
| Injury Severity Score | 1 | 2001 | 117 | 0.010 |
Why?
|
| Computer Communication Networks | 1 | 2000 | 12 | 0.010 |
Why?
|
| Models, Economic | 1 | 2000 | 42 | 0.010 |
Why?
|
| Dentists | 1 | 2000 | 12 | 0.010 |
Why?
|
| Systole | 1 | 2000 | 109 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1980 | 185 | 0.010 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2001 | 146 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2000 | 33 | 0.010 |
Why?
|
| Neuregulin-1 | 1 | 2000 | 3 | 0.010 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2000 | 9 | 0.010 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2000 | 9 | 0.010 |
Why?
|
| ras-GRF1 | 1 | 2000 | 3 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 2000 | 10 | 0.010 |
Why?
|
| Eating | 1 | 2001 | 137 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 97 | 0.010 |
Why?
|
| Ricinus | 1 | 1979 | 1 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2000 | 106 | 0.010 |
Why?
|
| Plant Lectins | 1 | 1979 | 7 | 0.010 |
Why?
|
| Plants, Toxic | 1 | 1979 | 13 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1979 | 40 | 0.010 |
Why?
|
| Video Recording | 1 | 2000 | 139 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2000 | 125 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2000 | 88 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2000 | 55 | 0.010 |
Why?
|
| Office Automation | 1 | 1999 | 1 | 0.010 |
Why?
|
| Integrated Advanced Information Management Systems | 1 | 1999 | 1 | 0.010 |
Why?
|
| GTPase-Activating Proteins | 1 | 2000 | 69 | 0.010 |
Why?
|
| Carbohydrates | 1 | 1979 | 40 | 0.010 |
Why?
|
| Water | 1 | 2001 | 314 | 0.010 |
Why?
|
| Portugal | 1 | 1999 | 3 | 0.010 |
Why?
|
| Spouse Abuse | 1 | 1999 | 44 | 0.010 |
Why?
|
| Program Development | 1 | 2000 | 208 | 0.010 |
Why?
|
| Teaching | 1 | 2000 | 164 | 0.010 |
Why?
|
| Maleates | 1 | 1979 | 1 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2001 | 410 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2000 | 151 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2000 | 518 | 0.010 |
Why?
|
| Urinalysis | 1 | 1999 | 37 | 0.010 |
Why?
|
| Electrophoresis, Cellulose Acetate | 1 | 1978 | 1 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1978 | 23 | 0.010 |
Why?
|
| Enterococcus | 1 | 1998 | 10 | 0.010 |
Why?
|
| Neutropenia | 1 | 1998 | 68 | 0.010 |
Why?
|
| Tooth Demineralization | 1 | 1998 | 1 | 0.010 |
Why?
|
| Tooth | 1 | 1998 | 4 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1978 | 193 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2000 | 493 | 0.010 |
Why?
|
| Peritonitis | 1 | 1998 | 43 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2000 | 341 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2000 | 302 | 0.010 |
Why?
|
| Periodicals as Topic | 1 | 2000 | 178 | 0.010 |
Why?
|
| Pregnancy Trimester, First | 1 | 1997 | 24 | 0.010 |
Why?
|
| Automation | 1 | 1997 | 55 | 0.010 |
Why?
|
| Lung | 1 | 2002 | 962 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2281 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1997 | 18 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1999 | 801 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1997 | 240 | 0.010 |
Why?
|
| Molar | 1 | 1997 | 4 | 0.010 |
Why?
|
| Parotid Gland | 1 | 1997 | 9 | 0.010 |
Why?
|
| Anilides | 1 | 1977 | 18 | 0.010 |
Why?
|
| Pennsylvania | 1 | 1997 | 66 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1997 | 37 | 0.010 |
Why?
|
| Potassium | 1 | 1997 | 97 | 0.010 |
Why?
|
| Software | 1 | 2000 | 399 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 1996 | 50 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1998 | 150 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1997 | 311 | 0.010 |
Why?
|
| Food | 1 | 1996 | 76 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 1976 | 83 | 0.010 |
Why?
|
| Administration, Topical | 1 | 1995 | 50 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2000 | 727 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2000 | 625 | 0.010 |
Why?
|
| New Hampshire | 1 | 1995 | 43 | 0.010 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1995 | 38 | 0.010 |
Why?
|
| North Carolina | 1 | 1995 | 69 | 0.010 |
Why?
|
| Dental Impression Materials | 1 | 1995 | 1 | 0.010 |
Why?
|
| Siloxanes | 1 | 1995 | 1 | 0.010 |
Why?
|
| Replica Techniques | 1 | 1995 | 1 | 0.010 |
Why?
|
| Freeze Drying | 1 | 1995 | 15 | 0.010 |
Why?
|
| Polynesia | 1 | 1994 | 1 | 0.010 |
Why?
|
| Pacific Islands | 1 | 1994 | 4 | 0.010 |
Why?
|
| Polyvinyls | 1 | 1995 | 19 | 0.010 |
Why?
|
| Acrylic Resins | 1 | 1995 | 21 | 0.010 |
Why?
|
| Yogurt | 1 | 1994 | 5 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1995 | 111 | 0.010 |
Why?
|
| Anthropometry | 1 | 1994 | 86 | 0.010 |
Why?
|
| Infusions, Parenteral | 2 | 1984 | 21 | 0.010 |
Why?
|
| Europe | 1 | 1994 | 199 | 0.010 |
Why?
|
| Keto Acids | 1 | 1974 | 2 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2000 | 1385 | 0.010 |
Why?
|
| Butyrates | 1 | 1974 | 16 | 0.010 |
Why?
|
| Phentolamine | 1 | 1993 | 7 | 0.010 |
Why?
|
| Tetrodotoxin | 1 | 1993 | 11 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1994 | 128 | 0.010 |
Why?
|
| Hypoxia, Brain | 1 | 1993 | 10 | 0.010 |
Why?
|
| Hepatitis | 1 | 1974 | 58 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1993 | 73 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2000 | 2094 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1994 | 371 | 0.010 |
Why?
|
| Rabbits | 1 | 1974 | 338 | 0.010 |
Why?
|
| Embryo Transfer | 1 | 1993 | 24 | 0.010 |
Why?
|
| Southeastern United States | 1 | 1993 | 26 | 0.010 |
Why?
|
| Inhibins | 1 | 1993 | 50 | 0.010 |
Why?
|
| Oxygen | 1 | 1995 | 319 | 0.010 |
Why?
|
| Tooth Exfoliation | 1 | 1992 | 1 | 0.010 |
Why?
|
| Adamantane | 1 | 1992 | 5 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1994 | 198 | 0.010 |
Why?
|
| Ovary | 1 | 1993 | 105 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 1992 | 40 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1994 | 299 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1995 | 361 | 0.010 |
Why?
|
| Pedigree | 1 | 1992 | 193 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1994 | 497 | 0.010 |
Why?
|
| Risk | 1 | 1993 | 374 | 0.010 |
Why?
|
| Estradiol | 1 | 1993 | 259 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1995 | 741 | 0.010 |
Why?
|
| Myocardium | 1 | 1974 | 301 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 1995 | 434 | 0.010 |
Why?
|
| Exercise Test | 1 | 1993 | 257 | 0.010 |
Why?
|
| Models, Statistical | 1 | 1993 | 309 | 0.010 |
Why?
|
| Fluoroimmunoassay | 1 | 1990 | 3 | 0.010 |
Why?
|
| Students | 1 | 1993 | 225 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 1991 | 117 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1989 | 106 | 0.000 |
Why?
|
| Computers | 2 | 1982 | 49 | 0.000 |
Why?
|
| Fetus | 1 | 1989 | 102 | 0.000 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1989 | 206 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1991 | 553 | 0.000 |
Why?
|
| Emergency Service, Hospital | 1 | 1996 | 1141 | 0.000 |
Why?
|
| Microsomes, Liver | 1 | 1987 | 16 | 0.000 |
Why?
|
| Vanadium | 1 | 1987 | 4 | 0.000 |
Why?
|
| Prostatitis | 1 | 1986 | 2 | 0.000 |
Why?
|
| Subcellular Fractions | 1 | 1987 | 67 | 0.000 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1987 | 45 | 0.000 |
Why?
|
| Prostate-Specific Antigen | 1 | 1986 | 84 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1987 | 144 | 0.000 |
Why?
|
| Cytosol | 1 | 1987 | 182 | 0.000 |
Why?
|
| Thermodynamics | 1 | 1986 | 196 | 0.000 |
Why?
|
| Mitochondria, Liver | 1 | 1985 | 13 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1986 | 277 | 0.000 |
Why?
|
| Adipates | 1 | 1984 | 1 | 0.000 |
Why?
|
| Sarcosine | 1 | 1984 | 3 | 0.000 |
Why?
|
| Lysine | 1 | 1984 | 94 | 0.000 |
Why?
|
| Glycylglycine | 1 | 1982 | 1 | 0.000 |
Why?
|
| Fibroblasts | 1 | 1984 | 421 | 0.000 |
Why?
|
| Thyroid Function Tests | 1 | 1976 | 14 | 0.000 |
Why?
|
| Transaminases | 1 | 1976 | 15 | 0.000 |
Why?
|
| Malate Dehydrogenase | 1 | 1975 | 3 | 0.000 |
Why?
|
| Alcohol Oxidoreductases | 1 | 1976 | 28 | 0.000 |
Why?
|
| Models, Chemical | 1 | 1975 | 137 | 0.000 |
Why?
|
| Hydrocortisone | 1 | 1976 | 192 | 0.000 |
Why?
|